CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Episodes 91-105 of 745
The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
MinuteCE®The Future of PI3K Inhibition in HR+/HER2- Breast Cancer
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
CME/CEBehind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CEReal-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Advances in Managing Neuropsychiatric Symptoms of Alzheimer’s Disease: From Early Detection to Emerging Therapies
CME/CEAdvances in Managing Neuropsychiatric Symptoms of Alzheimer’s Disease: From Early Detection to Emerging Therapies
Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
CME/CETest Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast ReplayCrossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
- advertisement
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast ReplayNew Insights in the Management of HCM: Exploring the Clinical Spectrum
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CEOptimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
MinuteCE®Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
- advertisement
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
Beyond GDMT: Timely Consideration of Barostim in Heart Failure
CME/CEBeyond GDMT: Timely Consideration of Barostim in Heart Failure
Optimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
CME/CEOptimizing IgAN Care: Sparsentan’s Role Amid the Latest KDIGO Guideline Updates
